Back

Impact of ferric carboxymaltose on left ventricular ejection fraction in iron-deficient heart failure patients of south asian descent

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - comorbidities (5) Comorbidities HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Dayana Gandi Abousaid

Krishna Institute of Medical Sciences, Hyderabad (India)

5 More presentations in this session

Presentation thumbnail
Biomarkers related to heart failure as predictors of incident stroke in the general population
Doctor N. Suthahar (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Impact of atrial fibrillation with rapid ventricular response in acute decompensated heart failure
Professor D. Aronson (Haifa, IL)
Abstract Slides Video
Presentation thumbnail
Association between high sensitivity C-reactive protein and neutrophil to lymphocyte ratio with frailty syndrome in heart failure with reduced ejection fraction.
Miss A. Szubarga (Poznan, PL)
Abstract Slides Video
Presentation thumbnail
The prognostic significance of iron deficiency in hospitalized heart failure patients
Miss X. Zhao (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Patiromer use for the treatment of hyperkaliemia in patients with heart failure and chronic kidney disease, real-world experience
Doctor L. Grau Torrente (Marbella, Malaga, ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - comorbidities (5)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Iron deficiency in patients with heart failure with improved left ventricular ejection fraction
thumbnail
Congress Presentation
Intravenous iron therapy for patients with heart failure and iron deficiency: an updated meta-analysis of randomized controlled trials
thumbnail
Congress Presentation
Myocardial performance improvement after iron replacement in heart failure patients with LVEF <50% and TSAT <20%: The IRON-PATH II echo-substudy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources